Comparable stake leader
Domicilium Real Estate Fund III LP
SEC ownership of Eloxx Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001035354.
Disclosed value leader
Aberdeen Group plc
Comparable rows
26/42
Latest evidence
30 Jun 2026
- Public ticker
- ELOX on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Domicilium Real Estate Fund III LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
26 of 42
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Domicilium Real Estate Fund III LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001035354
- Issuer location
- Arlington, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Eloxx Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Domicilium Real Estate Fu...
Disclosed value leader
Aberdeen Group plc
Comparable rows
26/42
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
16 rows are not safely comparable across share classes.
13D/G row: Domicilium Real Estate Fund III LP
Showing 1-8 of 42 holder rows.
Quick read
Domicilium Real Estate Fund III LP leads the comparable SEC ownership view at 20%.
26 of 42 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Domicilium Real Estate Fund III LP's linked filing trail.
Comparable ownership
Top 5
Domicilium Real Estate Fund III LP
20%
Coastlands Capital LP
10%
Invus Global Management, LLC
10%
Aberdeen Group plc
9.9%
Nantahala Capital Management, LLC
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 42 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Domicilium Real Estate Fund III LP |
3/4/5
13D/G
10%+ Owner · Domicilium Capital Partners LLC
|
20%
from 13D/G
|
$4,570,346
1,434,489 shares
mixed-class rows
|
— | 10 Jun 2026 |
| Coastlands Capital LP |
13D/G
3/4/5
10%+ Owner
|
10%
|
—
410,530 shares
|
$0 | 10 Jun 2026 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
10%
|
—
403,586 shares
|
$0 | 09 Jun 2026 |
| Aberdeen Group plc |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$5,552,000
400,000 shares
|
— | 30 Jun 2026 |
| Nantahala Capital Management, LLC |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$5,552,000
400,000 shares
|
— | 30 Jun 2026 |
| EcoR1 Capital, LLC |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$5,552,000
400,000 shares
|
— | 30 Jun 2026 |
| Stonepine Capital Management, LLC |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$5,512,581
397,160 shares
|
— | 30 Jun 2026 |
| Samsara BioCapital, L.P. |
13D/G
Srinivas Akkaraju
|
9.9%
|
$4,580,701
403,586 shares
|
$0 | 10 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Eloxx Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Domicilium Real Estate Fund III LP
Net 12M change
$0
Latest report
10 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Domicilium Real Estate Fund III LP | 10%+ Owner | $4,570,346 | Mixed | 10 Jun 2026 | ||
| Pontifax Management 4 G.P. (2015) Ltd. | 10%+ Owner | $443,946 | Mixed | 13 May 2021 | ||
| Sumit Aggarwal | President and CEO, Director | $43,200 | Mixed | 10 Jun 2026 | ||
| Daniel E. Geffken | Interim Cfo | $36,000 | Mixed | 29 Nov 2021 | ||
| Neil S. Belloff | Coo, General Counsel &Corp Sec | $30,293 | Mixed | 30 Jul 2021 | ||
| Steven D. Rubin | Director | $5,400 | Mixed | 08 Jun 2026 | ||
| Lindsay Androski | Director | $5,400 | Mixed | 24 Jan 2025 | ||
| Alan Edmund Walts | Director | $5,400 | Mixed | 08 Jun 2026 | ||
| Nina S. Kjellson | Director | Mixed | 08 Jun 2026 | |||
| Vijay Modur | Head Of R&D | Mixed | 25 Jan 2023 | |||
| Stephen W. Webster | Director | Mixed | 08 Jun 2026 | |||
| Gadi Veinrib | Director | Mixed | 15 Jun 2022 | |||
| Zafrira Avnur | Director | Mixed | 15 Jun 2022 | |||
| Jasbir Seehra | Director | Mixed | 15 Jun 2022 | |||
| Tomer Kariv | Director | Mixed | 30 Jan 2023 | |||
| Rajesh B. Parekh | Director | Mixed | 15 Jun 2022 | |||
| Ran Nussbaum | Director | Mixed | 15 Jun 2022 | |||
| Coastlands Capital LP | 10%+ Owner | Mixed | 27 May 2026 |
Recent insider transactions for Eloxx Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Domicilium Real Estate Fund III LP | ELOX | common stock, $0.01 par value per share | Other | 600,000 | 361,578 | 10 Jun 2026 | See footnote | |||
| Domicilium Real Estate Fund III LP | ELOX | Pre-funded Warrant | Other | 255.9% | 600,000 | 834,489 | 10 Jun 2026 | See footnote | ||
| Sumit Aggarwal | ELOX | Stock Option (Right to Buy) | Award | 328,833 | 328,833 | 10 Jun 2026 | Direct | |||
| Stephen W. Webster | ELOX | Stock Option (Right to Buy) | Award | 13,587 | 13,587 | 08 Jun 2026 | Direct | |||
| Alan Edmund Walts | ELOX | Stock Option (Right to Buy) | Award | 8,590 | 8,590 | 08 Jun 2026 | Direct | |||
| Nina S. Kjellson | ELOX | Stock Option (Right to Buy) | Award | 13,587 | 13,587 | 08 Jun 2026 | Direct | |||
| Steven D. Rubin | ELOX | Stock Option (Right to Buy) | Award | 4,018 | 4,018 | 08 Jun 2026 | Direct | |||
| Domicilium Real Estate Fund III LP | ELOX | Common Stock, $0.01 par value per share | Other | -100% | -113,636 | 0 | 27 May 2026 | Direct | ||
| Domicilium Real Estate Fund III LP | ELOX | Pre-funded Warrant | Other | 91.1% | 113,636 | 238,422 | 27 May 2026 | Direct | ||
| Coastlands Capital LP | ELOX | Common Stock | Other | -100% | -1,250,000 | 0 | 27 May 2026 | By Coastlands Capital LP | ||
| Coastlands Capital LP | ELOX | Pre-funded Warrant | Other | 4.26% | 1,250,000 | 30,612,243 | 27 May 2026 | By Coastlands Capital LP | ||
| Sumit Aggarwal | ELOX | Common Stock | Options Exercise | 18.5% | 260,946 | 1,672,756 | 28 Feb 2026 | Direct | ||
| Sumit Aggarwal | ELOX | Stock Option (Right to Buy) | Options Exercise | -7.25% | -260,946 | 3,336,144 | 28 Feb 2026 | Direct | ||
| Steven D. Rubin | ELOX | Common Stock | Options Exercise | 14.7% | 1,875 | 14,625 | 24 Jan 2026 | Direct | ||
| Steven D. Rubin | ELOX | Restricted Stock Units | Options Exercise | -50% | -1,875 | 1,875 | 24 Jan 2026 | Direct | ||
| Sumit Aggarwal | ELOX | Common Stock | Options Exercise | 1.07% | 15,000 | 1,411,810 | 24 Jan 2026 | Direct | ||
| Sumit Aggarwal | ELOX | Restricted Stock Units | Options Exercise | -50% | -15,000 | 15,000 | 24 Jan 2026 | Direct | ||
| Alan Edmund Walts | ELOX | Common Stock | Options Exercise | 13.7% | 1,875 | 15,567 | 24 Jan 2026 | Direct | ||
| Alan Edmund Walts | ELOX | Restricted Stock Units | Options Exercise | -50% | -1,875 | 1,875 | 24 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.